<DOC>
	<DOCNO>NCT00895011</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy two dos avanafil treatment adult male erectile dysfunction follow bilateral nerve-sparing radical prostatectomy .</brief_summary>
	<brief_title>Research Evaluating Investigational Medication Erectile Dysfunction - Post-Prostatectomy</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Adult male ≥ 18 year ≤ 70 year ; Have history erectile dysfunction least 6 month duration follow bilateral nervesparing retropubic radical prostatectomy ; Have PSA level consistent absence prostate cancer ; Have history sexual potency prior radical prostatectomy without require medical therapy ; Be monogamous , heterosexual relationship current partner least 3 month ; Provide write informed consent ; Agree make least 4 attempt intercourse per month ; Agree use treatment erectile dysfunction ; Be willing able comply study requirement ( include schedule study visit , treatment plan , laboratory test study procedure ) . Exclusion Criteria Allergy hypersensitivity PDE5 inhibitor component drug product ; History doselimiting AEs prior treatment PDE5 inhibitor discontinue use PDE5 inhibitor due lack efficacy high tolerate dose ; Concomitant use one follow medication : Any nitrate , trazodone , itraconazole , ketoconazole , erythromycin , cimetidine ; Other prescription OTC drug know interfere metabolism CYP 3A4 enzyme ; If receive hormone replacement therapy ( include thyroid supplementation ) , dose stable least 3 month ; If treat alpha blocker , dose stable least 14 day ; Erectile dysfunction consequence advance neurologic disease , spinal cord injury , diabetes ; History severe erectile dysfunction require medical therapy prior bilateral nervesparing radical prostatectomy ; History previous pelvic surgery , brachytherapy , cryotherapy prostate ; Sexual partner 18 year age , pregnant , intend become pregnant course study , breastfeeding , dyspareunia gynecologic condition major medical condition would interfere sexual activity would difficulty comply study requirement ; Uncontrolled hypertension ; Hypotension ; Orthostatic hypotension ; Myocardial infarction , stroke , lifethreatening arrhythmia coronary revascularization within past 6 month ; Unstable angina , angina sexual intercourse , congestive heart failure &gt; NYHA Class II ; History ECG evidence highrisk arrhythmia clinically significant ECG ; Hypertrophic , obstructive , clinically significant cardiomyopathy , moderate severe cardiac valvular disease ; Type 1 type 2 diabetes , history use antidiabetic medication ; Clinically evident penile lesion , abrasion , anatomical deformity penile fibrosis , Peyronie 's disease , penile implant , urinary tract bladder infection , sexually transmissible disease investigator deem clinically significant ; Condition ( ) predispose priapism , sickle cell disease , multiple myeloma , leukemia ; Any malignancy carcinoma prostate ( except basal cell carcinoma squamous cell carcinoma skin ) ; Prior use , likely require radiotherapy , chemotherapy , androgen deprivation therapy , cryotherapy , nonnervesparing surgery , and/or bladder penile surgery study ; Evidence significant hepatic impairment ; On dialysis , history renal transplantation ; Untreated hypogonadism low serum total testosterone ; Abnormal laboratory value ( ) judge clinically significant investigator ; Positive STD screen ( syphilis , gonorrhea , chlamydia ) ; Positive HIV , HCV Ab , HBsAg screening ; History current drug , alcohol , substance abuse ; Positive urine drug screen ; Positive breath alcohol test ; Retinitis pigmentosa nonarteritic anterior ischemic optic neuropathy ; Use treatment device treatment erectile dysfunction ; Use investigational medication device indication within 30 day prior enrollment time study ; Previous participation investigational study avanafil ; Any history bipolar disorder psychosis , great one lifetime episode major depression , current depression moderate great severity antidepressant use stable least 3 month ; Involvement plan conduct study part subject partner ; Evidence clinically significant medical , psychiatric , social condition history , physical examination laboratory study , opinion investigator , would contraindicate administration study medication , affect compliance , interfere study evaluation , limit study participation , contraindicate sexual activity confound interpretation study result .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>E.D .</keyword>
</DOC>